Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3369)
All Articles published online
|
Dec 21, 2009 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, Schuchmann M, Schulze-Bergkamen H. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009; 15(47): 5924-5935 [PMID: 20014456 DOI: 10.3748/wjg.15.5924] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i47/5924.htm |
| Number | Citing Articles |
| 1 |
Ya-Hui Huang, Ying-Hsin Tseng, Wey-Ran Lin, George Hung, Tse-Ching Chen, Tong-Hong Wang, Wei-Chen Lee, Chau-Ting Yeh. HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100. Oncotarget 2016; 7(8): 9448 doi: 10.18632/oncotarget.7021
|
| 2 |
Christian L. Barrett, Richard B. Schwab, HyunChul Jung, Brian Crain, Daniel J. Goff, Catriona H. M. Jamieson, Patricia A. Thistlethwaite, Olivier Harismendy, Dennis A. Carson, Kelly A. Frazer, Marc Lenburg. Transcriptome Sequencing of Tumor Subpopulations Reveals a Spectrum of Therapeutic Options for Squamous Cell Lung Cancer. PLoS ONE 2013; 8(3): e58714 doi: 10.1371/journal.pone.0058714
|
| 3 |
Yinglan Liu, Yingwei Wang, Yaling Zhang, Jianhua Fu, Guangmei Zhang. Knockdown of HMGA1 expression by short/small hairpin RNA inhibits growth of ovarian carcinoma cells. Biotechnology and Applied Biochemistry 2012; 59(1): 1 doi: 10.1002/bab.56
|
| 4 |
Inga Hochnadel, Uta Kossatz-Boehlert, Nils Jedicke, Henrike Lenzen, Michael P. Manns, Tetyana Yevsa. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Human Vaccines & Immunotherapeutics 2017; 13(12): 2931 doi: 10.1080/21645515.2017.1359362
|
| 5 |
Darren Finlay, Robyn D. Richardson, Lisa K. Landberg, Amy L. Howes, Kristiina Vuori, Andrei L. Gartel. Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis. PLoS ONE 2010; 5(10): e13375 doi: 10.1371/journal.pone.0013375
|
| 6 |
Wei Jiang, Dong-Bo Wu, Si-Yu Fu, En-Qiang Chen, Hong Tang, Tao-You Zhou. Insight into the role of TRAIL in liver diseases. Biomedicine & Pharmacotherapy 2019; 110: 641 doi: 10.1016/j.biopha.2018.12.004
|
| 7 |
Nehal M. Elsherbiny, Nada H. Eisa, Mohamed El-Sherbiny, Eman Said. Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathways. Environmental Toxicology and Pharmacology 2020; 80: 103494 doi: 10.1016/j.etap.2020.103494
|
| 8 |
Alvaro Mordente, Elisabetta Meucci, Andrea Silvestrini, Giuseppe Ettore Martorana, Bruno Giardina. Advances in Mitochondrial Medicine. Advances in Experimental Medicine and Biology 2012; 942: 385 doi: 10.1007/978-94-007-2869-1_18
|
| 9 |
T Lu, N Shao, C Ji. Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells. Cancer Gene Therapy 2013; 20(1): 33 doi: 10.1038/cgt.2012.81
|
| 10 |
ZHAOJUN WAN, HUAZHENG PAN, SHIHAI LIU, JINGJUAN ZHU, WEIWEI QI, KAI FU, TENG ZHAO, JUN LIANG. Downregulation of SNAIL sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by regulating the NF-κB pathway. Oncology Reports 2015; 33(3): 1560 doi: 10.3892/or.2015.3743
|
| 11 |
Duan Wu, Ouyang Hao, Weiye Hu, Zhaorong Wu, Linke Bian, Hongye Wang, Junfeng Zhu. Circulating cytokines and alcoholic liver disease: a two-sample bidirectional Mendelian randomization study. Scandinavian Journal of Gastroenterology 2024; 59(3): 325 doi: 10.1080/00365521.2023.2286190
|
| 12 |
Bruno Christian Koehler, Adam Jassowicz, Anna-Lena Scherr, Stephan Lorenz, Praveen Radhakrishnan, Nicole Kautz, Christin Elssner, Johanna Weiss, Dirk Jaeger, Martin Schneider, Henning Schulze-Bergkamen. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1929-y
|
| 13 |
Guan Wang, Yao Zhan, Haiqing Wang, Wenhua Li. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemotherapy and Pharmacology 2012; 69(3): 799 doi: 10.1007/s00280-011-1763-0
|
| 14 |
Kuen‐Feng Chen, Hui‐Ling Chen, Chung‐Wai Shiau, Chun‐Yu Liu, Pei‐Yi Chu, Wei‐Tien Tai, Kimihisa Ichikawa, Pei‐Jer Chen, Ann‐Lii Cheng. Sorafenib and its derivative SC‐49 sensitize hepatocellular carcinoma cells to CS‐1008, a humanized anti‐TNFRSF10B (DR5) antibody. British Journal of Pharmacology 2013; 168(3): 658 doi: 10.1111/j.1476-5381.2012.02212.x
|
| 15 |
Bruno Christian Koehler, Anna-Lena Scherr, Stephan Lorenz, Toni Urbanik, Nicole Kautz, Christin Elssner, Stefan Welte, Justo Lorenzo Bermejo, Dirk Jäger, Henning Schulze-Bergkamen, Jun Li. Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro. PLoS ONE 2013; 8(10): e76446 doi: 10.1371/journal.pone.0076446
|
| 16 |
Inas Almazari, Young-Joon Surh. Natural Products in Cancer Prevention and Therapy. Topics in Current Chemistry 2012; 329: 35 doi: 10.1007/128_2012_344
|
| 17 |
KEIICHIRO NOJIRI, KAZUSHI SUGIMOTO, KATSUYA SHIRAKI, MASAHIKO TAMEDA, YUUJI INAGAKI, SUGURU OGURA, CHIKA KASAI, SATOKO KUSAGAWA, MISAO YONEDA, NORIHIKO YAMAMOTO, YOSHIYUKI TAKEI, TSUTOMU NOBORI, MASAAKI ITO. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. International Journal of Oncology 2013; 42(1): 101 doi: 10.3892/ijo.2012.1676
|
| 18 |
Vivek Subbiah, Robert E. Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock. Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist. Molecular Cancer Therapeutics 2012; 11(11): 2541 doi: 10.1158/1535-7163.MCT-12-0358
|
| 19 |
Lu Deng, Chang Wang, Chao He, Li Chen. Bone mesenchymal stem cells derived extracellular vesicles promote TRAIL-related apoptosis of hepatocellular carcinoma cells via the delivery of microRNA-20a-3p. Cancer Biomarkers 2021; 30(2): 223 doi: 10.3233/CBM-201633
|
| 20 |
T. Ciuleanu, I. Bazin, D. Lungulescu, L. Miron, I. Bondarenko, A. Deptala, M. Rodriguez-Torres, B. Giantonio, N.L. Fox, P. Wissel, J. Egger, M. Ding, R.N. Kalyani, R. Humphreys, M. Gribbin, W. Sun. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Annals of Oncology 2016; 27(4): 680 doi: 10.1093/annonc/mdw004
|
| 21 |
Yuki Haga, Tatsuo Kanda, Masato Nakamura, Shingo Nakamoto, Reina Sasaki, Koji Takahashi, Shuang Wu, Osamu Yokosuka, Olorunseun Ogunwobi. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. PLOS ONE 2017; 12(3): e0174153 doi: 10.1371/journal.pone.0174153
|
| 22 |
Jorn Markus Schattenberg, Marcus Schuchmann, Peter Robert Galle. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. Journal of Gastroenterology and Hepatology 2011; 26(s1): 213 doi: 10.1111/j.1440-1746.2010.06582.x
|
| 23 |
Martin Franz Sprinzl, Florian Reisinger, Andreas Puschnik, Marc Ringelhan, Kerstin Ackermann, Daniel Hartmann, Matthias Schiemann, Arndt Weinmann, Peter Robert Galle, Marcus Schuchmann, Helmut Friess, Gerd Otto, Mathias Heikenwalder, Ulrike Protzer. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013; 57(6): 2358 doi: 10.1002/hep.26328
|
| 24 |
Dawei Zhang, Jianping Liu, Yang Wang, Jie Chen, Tao Chen. shRNA‐mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL‐induced apoptosis. Journal of Cellular Biochemistry 2011; 112(11): 3140 doi: 10.1002/jcb.23240
|
| 25 |
M Siegemund, N Pollak, O Seifert, K Wahl, K Hanak, A Vogel, A K Nussler, D Göttsch, S Münkel, H Bantel, R E Kontermann, K Pfizenmaier. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death & Disease 2012; 3(4): e295 doi: 10.1038/cddis.2012.29
|
| 26 |
Venturina Stagni, Simonetta Santini, Daniela Barilà. A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase. Cancers 2012; 4(2): 354 doi: 10.3390/cancers4020354
|
| 27 |
Gianluigi Giannelli, Bhavna Rani, Francesco Dituri, Yuan Cao, Giuseppe Palasciano. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 2014; 63(10): 1668 doi: 10.1136/gutjnl-2014-307323
|